PsiloTec Health Solutions Inc., operating as Zylorion Health, has filed its third provisional patent application with the United States Patent and Trademark Office (USPTO).
Zylorion Health is focused on precision mental health care and psychedelic therapy. The provisional patent application covers the composition of matter of Zylorion’s novel psilocybin-based compound, ZYL-314.
The compound will be used for the treatment of mental health disorders and other central nervous system conditions and cognitive disorders.
CEO, Dr Peter Silverstone, commented: “Our clinical team has been working tirelessly with our research partners on the development of novel second generation and industry leading compounds, and we are extremely excited about this discovery.
“ZYL-314 is truly unique and achieving this milestone demonstrates Zylorion’s commitment to bringing innovative new therapies to market and creating long-term shareholder value through a strong portfolio of intellectual property assets.”
The company continues to gather the necessary data and evidence to support the claims and conversion of the composition of matter provisional patent and anticipates filing an application under the PCT (Patent Cooperation Treaty) within the next twelve months.
Zylorion is currently engaged in the development and delivery of integrated precision mental health therapies to address psychological and neurological mental health conditions.
It is focussing on the research, development and commercialisation of psychedelic-based compounds coupled with novel therapeutic treatment programmes targeting a continuum of mental health conditions, such as major depressive disorder, treatment resistant depression, post-traumatic stress disorder, general depression, anxiety disorders, and a number of addictive tendencies.
Zylorion has stated that it aims to leverage leading technologies to support the scalability and accessibility of its integrated therapy programmes in its mission to enable those experiencing mental health challenges to thrive.
[activecampaign form=52]
